Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.061
- Book/Share 15.3114
- PB 7.4278
- Debt/Equity 1.3022
- CurrentRatio 1.3693
- ROIC 0.1532
- MktCap 142094123900.0
- FreeCF/Share 7.9005
- PFCF 14.4346
- PE 23.861
- Debt/Assets 0.4421
- DivYield 0.0273
- ROE 0.3171
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | GILD | Needham | Hold | Buy | -- | $133 | July 25, 2025 |
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
| Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
| Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
| Upgrade | GILD | Morgan Stanley | Equal Weight | Overweight | $87 | $113 | Jan. 10, 2025 |
| Resumed | GILD | BofA Securities | -- | Buy | -- | $109 | Dec. 10, 2024 |
| Upgrade | GILD | Leerink Partners | Market Perform | Outperform | $74 | $96 | Oct. 21, 2024 |
| Initiation | GILD | Bernstein | -- | Outperform | -- | $105 | Oct. 17, 2024 |
| Upgrade | GILD | Wells Fargo | Equal Weight | Overweight | $78 | $100 | Oct. 7, 2024 |
News
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Final Trades: Gilead, Blackstone, Disney and Visa
Published: July 25, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Calls of the Day: Gilead, Chipotle and P&G
Published: July 25, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in the 7 major markets (US, France, Germany, Italy, Spain, UK, Japan). Optimize your strategic approach with pipeline insights and competitive assessment. Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in the 7 major markets (US, France, Germany, Italy, Spain, UK, Japan). Optimize your strategic approach with pipeline insights and competitive assessment.
Read More
Why Merck Is A Better Dividend Stock Than Gilead Sciences
Published: July 16, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate my Hold rating on Merck & Co., Inc. and downgrade Gilead Sciences, Inc. to Sell, as MRK outperforms on dividend growth and valuation metrics. Compared to GILD, MRK features a longer dividend growth streak, a higher recent dividend increase, and a superior PEGY ratio. Both companies have similar payout ratios and mixed buyback histories, but GILD's inventory management is notably better than MRK's.
Read More
WHO recommends Gilead's twice-yearly injection for HIV prevention
Published: July 14, 2025 by: Reuters
Sentiment: Positive
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.
Read More
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
Published: July 09, 2025 by: Benzinga
Sentiment: Negative
Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead's twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).
Read More
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Final Trades: Synovus, Nextera Energy, Gilead and the IYF
Published: July 08, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Gilead Sciences (GILD) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Read More
Gilead shares rise after US top court ruling on preventative coverage
Published: June 27, 2025 by: Reuters
Sentiment: Positive
Shares of Gilead rose nearly 3% after the U.S. Supreme Court on Friday preserved a key element of the Obamacare law that helps guarantee that health insurers cover preventive care at no cost to patients.
Read More
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Gilead partners with Kymera to develop novel cancer therapy
Published: June 25, 2025 by: Proactive Investors
Sentiment: Positive
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on developing a novel cancer treatment targeting cyclin-dependent kinase 2 (CDK2), a protein that plays a key role in tumor growth. This collaboration aims to accelerate the development and commercialization of a new class of drugs called molecular glue degraders (MDGs), which work by selectively removing the CDK2 protein from cancer cells rather than merely inhibiting its function.
Read More
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
Published: June 25, 2025 by: Reuters
Sentiment: Positive
Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.
Read More
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Gilead's twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead
Published: June 18, 2025 by: Proactive Investors
Sentiment: Positive
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS)'s twice-yearly injectable HIV prevention drug lenacapavir is on track for a solid launch after being officially approved by the US Food and Drug Administration (FDA) on Wednesday, analysts at Jefferies believe. Lenacapavir, marketed as Yeztugo, is the first pre-exposure prophylaxis (PrEP) drug requiring only two treatments per year, offering a significant convenience advantage over daily oral PrEP and cabotegravir, which requires six injections per year.
Read More
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Published: June 18, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company's injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the United States for people who need or want PrEP. Data show that ≥99.9% of partici.
Read More
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
Published: June 18, 2025 by: CNBC
Sentiment: Positive
The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending the decades-long epidemic caused by the virus.
Read More
US FDA approves Gilead's twice-yearly injection for HIV prevention
Published: June 18, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.
Read More
Should You Buy Gilead Stock At $110?
Published: June 18, 2025 by: Forbes
Sentiment: Neutral
Despite a recent setback with an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P 500's modest 2% gain. The company is actively collaborating with authorities to resolve the recent issues and remains focused on improving profitability.
Read More
GILD ALERT: Ongoing Investigation Into Gilead Sciences, Inc. - Contact Levi & Korsinsky
Published: June 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte …
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel P. O'Day
- Employees 17600